Merus MRUS 深 滬
等待開盤 09-09 09:30:00 美东时间
67.19
-0.280
-0.41%
華盛通- 最 高67.8061
- 今 開67.13
- 成交量 48.21万股
- 最 低 66.025
- 昨 收 67.47
- 總市值 50.04亿
- 52周最高 69.20
- 市盈率 靜 --
- 換手率 0.65%
- 52周最低 33.19
- 委 比 -69.09%
- 總股本 7447.67万
- 歷史最高 69.20
- 量 比 0.83
- 振 幅 2.64%
- 歷史最低 7.255
- 每 手 1
- 風險率 8.10%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Merus to Present at the 2025 Wells Fargo Healthcare Conference
Merus N.V., an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®), announced that CEO Bill Lundberg, M.D., will participate in a fireside chat at the 2025 Wells Fargo Healthcare Conference on September 4 at 3:45 p.m. ET. The presentation will be available live and archived on the Company's Investors page.
08-28 12:00
Alliance Global Partners Initiates Coverage On Merus with Buy Rating, Announces Price Target of $90
Alliance Global Partners analyst Matt Venezia initiates coverage on Merus (NASDAQ:MRUS) with a Buy rating and announces Price Target of $90.
08-25 20:35
Skechers, Tesla, and DoorDash among hedge funds’ new favorite long positions – GS
Goldman Sachs strategists highlighted their “VIP” list of stocks that “matter the most” to hedge funds, as they appear the most among their top 10 holdings. This list has outperformed the S&P 500 (SP5...
08-21 01:25
Merus shares are trading lower after the company reported worse-than-expected Q2 financial results.
Merus shares are trading lower after the company reported worse-than-expected Q...
08-06 23:44
Needham Maintains Buy on Merus, Lowers Price Target to $96
Needham analyst Ami Fadia maintains Merus (NASDAQ:MRUS) with a Buy and lowers the price target from $97 to $96.
08-06 20:38
Merus to Present at the Canaccord Genuity 45th Annual Growth Conference
<p>Merus N.V., a biotech company specializing in innovative antibody therapies, has announced that its CEO, Bill Lundberg, M.D., will participate in a fireside chat at the Canaccord Genuity 45th Annual Growth Conference on August 13, 2025, at 1:30 p.m. ET. The event will be webcast live and archived on the company's Investors page. Merus is focused on developing full-length multispecific antibodies and antibody drug conjugates, which have shown p...
08-06 12:00
Merus N.V. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Merus N.V. granted 240,000 stock options to two new employees on August 1, 2025, as an inducement award outside its 2016 Incentive Award Plan. The options have an exercise price of $65.56 per share, a ten-year term, and vest over four years. The Board of Directors and independent directors approved the grant based on the Compensation Committee’s recommendation. The awards are subject to continuous service and the Plan’s terms.
08-04 20:01
贝达药业MCLA-129和恩沙替尼联合用药临床试验申请获受理
近日，贝达药业收到国家药品监督管理局（以下简称“NMPA”）签发的《受理通知书》（受理号：CXSL2500542、CXHL2500646、CXHL250064...
08-01 04:37
贝达药业MCLA-129在驱动基因阳性及MET扩增NSCLC研究中完成首例患者入...
7月29日，贝达药业注射用MCLA-129在肺癌领域开展的一项关于驱动基因阳性以及MET扩增相关的II期研究完成首例患者入组。 该研究全称为“一项评价抗EGF...
07-29 18:57
Mercury Systems to Report Fourth Quarter and Full Year Fiscal Year 2025 Financial Results on August 11, 2025
Mercury Systems Inc. will release its fourth quarter and full year fiscal year 2025 financial results on August 11, 2025, after market close. Management will host a conference call and webcast at 5:00 p.m. ET on the same day to discuss the financial results, business highlights, and outlook. Participants can register online in advance or at least 15 minutes before the call at [ir.mrcy.com/events-presentations](https://www.globenewswire.com/Tracke...
07-21 20:15
